Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCL001
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Cell Therapies
- Administration
- Intra-arterial
01
Overview
HCL001 is an allogeneic hepatocyte cell therapy developed by RenJi Hospital for the treatment of decompensated cirrhosis. The therapy consists of homologous hepatocytes derived from healthy donors, which are administered via hepatic artery infusion using a digital subtraction angiography (DSA) procedure. The therapeutic objective is to provide functional metabolic support to the failing liver and potentially stimulate endogenous liver regeneration, thereby improving liver function and clinical outcomes in patients with end-stage liver disease who have limited treatment options.
- Other names
- homologous allogeneic hepatocytesHCL001 cell injectionHCL-001 cell injectionHCL 001 cell injection
Beyond the preview
Go deeper on HCL001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCL001.